- ¥231bn
- ¥159bn
- ¥171bn
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)
Brief: Nippon Shinyaku Co Says Johnson & Johnson Obtains Approval Of Opsumit
Capricor jumps to 8-year high as cell therapy slows muscle-wasting disease
Table: Nippon Shinyaku 6-MTH group results (IFRS)
Brief: FDA Grants Orphan Drug Designation To Ns-051/Ncnp-04 For Treatment Of Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -Q1 group results (IFRS)
Table: Nippon Shinyaku -2024/25 parent results
Table: Nippon Shinyaku -2024/25 group results (IFRS)
Brief: FDA Grants Orphan Drug Designation By NS Pharma To Ns-229 For Treatment Of Eosinophilic Granulomatosis With Polyangiitis
Table: Nippon Shinyaku -9-MTH group results (IFRS)
Brief: Ab2 Bio Signs Agreement With Nippon Shinyaku For Tadekinig Alfa
Brief: REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
Regenxbio rises on partnership with Japan's Nippon Shinyaku
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Table: Nippon Shinyaku 6-MTH group results (IFRS)
Wave Life continues surge after DMD drug data impresses